Inclusion Criteria:  Participant has histologically confirmed locally advanced/metastatic (stage IIIB/IIIC or IV) Participant has a KRAS G12C mutation present in tumor tissue prior to enrollment, as determined by a Novartis designated central laboratory. Participants has received one prior platinum-based chemotherapy regimen and one prior immune checkpoint inhibitor therapy for locally advanced or metastatic disease Participant has at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1 at the screening visit.  Exclusion Criteria:  Participant has previously received docetaxel, KRAS G12C inhibitor or any other systemic therapy for their locally advanced or metastatic NSCLC other than one platinum-based chemotherapy and one prior immune check point inhibitor Participant has EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis Participant has an history of interstitial lung disease or pneumonitis grade > 1.  Other inclusion/exclusion criteria may apply